The Tmunity management team has extensive scientific, clinical, regulatory and commercial experience related to cell and gene therapies.
Vijay Reddy, MD
Dr. Reddy has significant experience in cancer research including immuno-oncology, having started his career as a medical oncologist at MD Anderson Cancer Center. Dr. Reddy also has significant experience in oncology drug development: he developed the CAR-T cell clinical program with first-in-class targets in his most recent role with Autolus Ltd., and played a critical role bringing new therapies to market at Janssen Pharmaceutical Companies and GlaxoSmithKline. His prior work in cellular engineering and tumor biology – specifically in solid tumors – will support Tmunity’s strategy of investigating multiple modalities for unique, targeted antigens to speed time to the clinic for people currently out of time and options because of their cancer diagnosis. Dr. Reddy has published numerous oncology papers, and holds a Bachelor of Medicine and Bachelor of Surgery from Sri Venkateshwara Medical College, and a Doctorate of Medicine in biochemistry from All India Institute of Medical Sciences.
David M. Barrett, MD/PhD
Dr. Barrett directs Translational Research at Tmunity, joining in 2020 after more than a decade in cell therapy research and clinical care at the Children’s Hospital of Philadelphia. Dr. Barrett first began collaborating with Tmunity founder Carl June in 2008 on the mouse models of CAR T cell endodomains, helping provide pre-clinical support for the construct that became known as Kymriah. As a physician-scientist, he cared for the first pediatric CAR T cell patients at CHOP while running an independent research lab. He has more than 60 publications on the preclinical development of CAR T cells (including diverse targets like GPC2 and CD38) and translational studies on clinical trial samples investigating toxicity and efficacy. Landmark studies include the first clinical report of two children with acute lymphoblastic leukemia treated with CAR T cells (NEJM), the first report of antigen escape from CAR T cells (NEJM, Cancer Discovery), the first report of the role of macrophages in CRS (Cytotherapy) and the character of quality starting material for manufacture (Science Translational Medicine).
Dr. Barrett first completed a Master of Science in Biomedical Engineering in 1997 before going on to complete his combined MD/PhD (Molecular Biology and Genetics) at Virginia Commonwealth University in 2004. He moved to the Children’s Hospital of Philadelphia for his residency in pediatrics, completed in 2007, and his fellowship in pediatric hematology/oncology, which he finished in 2010. He was an Assistant Professor in Pediatrics at the University of Pennsylvania and an attending physician in the Children’s Hospital of Philadelphia Division of Oncology, Transplant and Cellular Therapy Section until 2020.
Dr Karen Chagin
Dr. Karen Chagin is highly experienced in clinical development including extensive experience in cellular therapy. She spent nearly a decade building cellular therapy programs from proof of concept to the late-stage clinical setting. Previously, Dr. Chagin was Vice President of Clinical Development at Adaptimmune LLC, where she was responsible for the strategy and execution of global clinical development programs studying novel engineered T-cell receptor therapies in solid tumors on a global platform. Prior to that, she served as a Scientific Director in Oncology Early Development at Janssen leading development activities for Phase 1 assets. Dr. Chagin began her career in the pharmaceutical industry at GlaxoSmithKline. As Medical Director in clinical development at GSK, she was responsible for the development and execution of multiple Phase 2 and 3 clinical studies in a variety of solid and hematologic malignancies. Dr. Chagin also led and contributed to the registration of several oncology products and indications globally.
Dr. Chagin trained as a pediatric Hematologist/Oncologist at The Children’s Hospital of Philadelphia and holds and M.D from Temple University School of Medicine.